Federal healthcare programs are often well-intended but end up costing more than expected and become subject to waste, fraud, abuse, and mismanagement. One of the best (or worst) examples of such a result is the 340B Drug Pricing Program, which is administered by the Health Resources and Services Administration (HRSA). The lack of clear intent […]
The Congressional Budget Office (CBO) has confirmed what the Council for Citizens Against Government Waste (CCAGW) has long been saying about the 340B drug discount program. The September 9, 2025, CBO report noted that 340B has grown substantially and increases costs for taxpayers. The CBO report also underscores several reasons why reforms to the 340B […]
The 340B Drug Discount Program was created in 1992 to help federally funded clinics and public hospitals that serve a large uninsured population cover the cost of drugs and provide discounts to patients. But the lack of guardrails on the program and failure to define a patient has led to it being abused by hospitals […]
The federal 340B Drug Pricing Program was intended to provide discounts on drugs to patients but the lack of a clear intent and patient definition, along with inadequate oversight, has led to the program being exploited by hospitals and contract pharmacies to generate millions of dollars in profit. The discounts are supposed to be provided […]
This Week in Waste – May 9, 2025 Welcome to This Week in Waste, a series by Citizens Against Government Waste (CAGW) that highlights how taxpayer dollars are being wasted in the federal, state and local levels of government, and efforts to fight back against this spendthrift behavior. CAGW Files Comments to Department of Commerce […]
President Trump has made government efficiency a top priority. These efforts include eliminating improper payments and ensuring that only those who are eligible for government programs receive the benefits, including Medicaid. As President Trump said on “Meet the Press” on Sunday, May 4, 2025, “if illegal immigrants are in the mix, if people that aren’t […]
President Trump’s EO addresses the dual objectives of lowering drug prices while promoting innovation and protecting IP
340B reform should not only should be acted on by Congress, but also reviewed by DOGE.
The 340B Drug Pricing Program allows hospitals to prioritize profits over patients.
Minnesota Department of Health 340B report is the first at the state level to show costs and abuses of the program.
